- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03225716
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
A Phase 1/2 Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase I/II clinical trial. A Phase I clinical trial tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved Ulocuplumab as a treatment for any disease. Ulocuplumab is a type of protein called an antibody that attacks CXCR4, a protein that is found on B-cells like WM.
The FDA (the U.S. Food and Drug Administration) has Ibrutinib as a treatment option for this disease.
Ibrutinib has been under investigation in research studies in participants with recurrent B-cell lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and prolymphocytic leukemia, and WM. In a study of ibrutinib in relapsed/refractory WM patients, response rates were high and the treatment was well tolerated. In that study participants who had a CXCR4 mutation had a lower response rate to ibrutinib than those without a mutation.
In this research study, the investigators are evaluating the safety of ulocuplumab in combination with ibrutinib participants with symptomatic WM who have a CXCR4 mutation. The investigators are also evaluating how well the ulocuplumab works in combination with ibrutinib
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia and meeting criteria for treatment using consensus panel criteria from the Second International Workshop on Waldenstrom's macroglobulinemia (Kyle et al, 2003) or have high risk disease with an serum IgM level of 6,000 mg or higher (Gustine et al, 2016).
- MYD88 and CXCR4 mutated disease (determined by Treon laboratory or molecular diagnostics laboratory).
- Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of >2 times the upper limit of normal of each institution is required.
- Age ≥ 18 years
- ECOG performance status < or = 2 (see Appendix A.).
To establish eligibility, participants must have adequate organ and marrow function as defined below:
- Absolute neutrophil count ≥ 1,000/uL
- Platelets ≥ 75,000/uL
- Hemoglobin ≥ 8 g/dL
- Total bilirubin ≤ 1.5 mg/dL or < 2 mg/dL if attributable to hepatic infiltration by neoplastic disease or Gilbert's syndrome
- AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional upper limit of normal
- Creatinine ≤ 2 mg/dL
- Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin.
- Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or have or will have complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) while participating in the study; and 2) for at least 28 days after discontinuation from the study. Men must agree to use a latex condom during sexual contact with a FCBP even if the participants have had a successful vasectomy. FCBP must be referred to a qualified provider of contraceptive methods if needed. FCBP must have a negative serum pregnancy test at screening.
- Able to adhere to the study visit schedule and other protocol requirements.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Any serious medical condition, laboratory abnormality, uncontrolled intercurrent illness, or psychiatric illness/social condition that would prevent study participation.
- Concurrent use of any other anti-cancer agents or treatments or any other investigational agents.
- Treatment with strong CYP3A4/5 and/or CYP2D6 inhibitors
- Prior exposure to ibrutinib or ulocuplumab
- With the exception of low-dose aspirin, subjects enrolled in this study should not take concomitant medications that durably inhibit platelet function including marine oil tablets. For such medications a wash-out period of ≥ 7 days is required prior to starting treatment. Agents which inhibit platelet function transiently or inhibit coagulation by other mechanisms are restricted (e.g. use with caution). Medications that directly and durably inhibit platelet function include aspirin containing combinations, clopidogrel, dipyridamole, tirofiban, epoprostenol, eptifibatide, cilostazol, abciximab, ticlopidine, cilostazol.
- Participants should not take drugs that directly and durably inhibit coagulation with the exception of warfarin (coumadin) and heparin including low-molecular-weight heparin (LMWH), including enoxaparin, tinzaparin, etc.
- Any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- Known CNS lymphoma.
- New York Heart Association classification III or IV heart failure.
- Known history of Human Immunodeficiency Virus (HIV), active infection with Hepatitis B Virus (HBV), and/or Hepatitis C Virus (HCV).
- Lactating or pregnant women.
- Grade > 2 toxicity (other than alopecia) continuing from prior anti-cancer therapy.
- Inability to swallow capsules
- History of non-compliance to medical regimens.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ibrutinib + Ulocuplumab
|
Ulocuplumab is a type of protein called an antibody that attacks CXCR4
Other Names:
Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose of Ulocuplumab
Time Frame: 1 year
|
Determine the maximum dose or maximum tolerated dose from the Phase I dose escalation based on the number of dose limiting toxicities in each cohort.
|
1 year
|
Major Response Rate
Time Frame: 2 years
|
Major Response Rate= Partial response (>50% reduction in serum IgM from baseline) + Very Good Partial Response (>90% reduction in serum IgM from baseline) + Complete Response (resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly)
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Minor Response
Time Frame: 2 years
|
Time in months to >25%-50% reduction in serum IgM from baseline
|
2 years
|
Time to Major Response
Time Frame: 2 years
|
Time in months to >50-90% reduction in serum IgM from baseline
|
2 years
|
Time to Progression
Time Frame: 2 years
|
Time in months until >25% increase in serum IgM from nadir
|
2 years
|
Overall Response Rate
Time Frame: 2 years
|
Overall Response Rate= Minor response (>25%-50% reduction in serum IgM from baseline) + Partial Response (>50-90% reduction in serum IgM from baseline) + Very Good Partial Response (>90% reduction in serum IgM from baseline) + Complete Response (resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly).
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Steven P. Treon, MD, PhD, Dana-Farber Cancer Institute
Publications and helpful links
General Publications
- Kipps TJ. Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. Cancer J. 2021 Jul-Aug 01;27(4):306-313. doi: 10.1097/PPO.0000000000000536.
- Treon SP, Meid K, Hunter ZR, Flynn CA, Sarosiek SR, Leventoff CR, White TP, Cao Y, Roccaro AM, Sacco A, Demos MG, Guerrera ML, Kofides A, Liu X, Xu L, Patterson CJ, Munshi M, Tsakmaklis N, Yang G, Ghobrial IM, Branagan AR, Castillo JJ. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstrom macroglobulinemia. Blood. 2021 Oct 28;138(17):1535-1539. doi: 10.1182/blood.2021012953.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Waldenstrom Macroglobulinemia
Other Study ID Numbers
- 17-235
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Waldenstrom's Macroglobulinemia
-
Weill Medical College of Cornell UniversityMayo Clinic; Janssen Scientific Affairs, LLCTerminatedWaldenstrom Macroglobulinemia | Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia Refractory | Waldenstrom's Disease | Waldenström; Hypergammaglobulinemia | Waldenstrom's Macroglobulinemia of Lymph Nodes | Waldenstrom's Macroglobulinaemia, Without Mention of RemissionUnited States
-
BeiGeneRecruitingWaldenstrom Macroglobulinemia | Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia RefractoryUnited States, Australia, China, Spain, United Kingdom
-
Beijing InnoCare Pharma Tech Co., Ltd.CompletedWaldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia RefractoryChina
-
Fondazione Italiana Linfomi ONLUSCompletedWaldenstrom's MacroglobulinemiaItaly
-
Dana-Farber Cancer InstituteMillennium Pharmaceuticals, Inc.CompletedWaldenstrom's MacroglobulinemiaUnited States
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Millennium Pharmaceuticals, Inc.CompletedWaldenstrom's MacroglobulinemiaUnited States
-
Dana-Farber Cancer InstituteNovartis; Millennium Pharmaceuticals, Inc.TerminatedWaldenstrom's MacroglobulinemiaUnited States
-
Idera Pharmaceuticals, Inc.TerminatedWaldenstrom's MacroglobulinemiaUnited States
-
Dana-Farber Cancer InstituteAmgenCompletedWaldenstrom's MacroglobulinemiaUnited States
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaboratorsTerminatedWaldenstrom's MacroglobulinemiaUnited States
Clinical Trials on Ulocuplumab
-
Bristol-Myers SquibbTerminatedSolid TumorUnited States, Finland
-
Bristol-Myers SquibbTerminatedLeukemiaTaiwan, United States, Brazil, Japan, Italy, Korea, Republic of, Canada, China, Israel, Romania
-
Dana-Farber Cancer InstituteBristol-Myers SquibbNo longer availableMultiple Myeloma | Multiple Myeloma in RelapseUnited States